Shopping Cart
Remove All
Your shopping cart is currently empty
BAY885
Copy Product Info
🥰Excellent
Catalog No. T10479Cas No. 2307249-33-6
BAY885 is a new ERK5 inhibitor.
BAY885
Copy Product Info🥰Excellent
Purity: 99.83%
Catalog No. T10479Cas No. 2307249-33-6
BAY885 is a new ERK5 inhibitor.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $44 | In Stock | In Stock | |
| 5 mg | $155 | In Stock | In Stock | |
| 10 mg | $246 | In Stock | In Stock | |
| 25 mg | $446 | In Stock | In Stock | |
| 50 mg | Preferential | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $177 | In Stock | In Stock |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Purity:99.83%
Appearance:Solid
Color:White
Contact us for more batch information
Product Introduction
BAY885 AI Summary
BAY885 demonstrates significant bioactivities related to the inhibition of specific enzymes and cellular processes. It inhibits His-tagged MAP2K5 activated ERK5 with an IC50 of 35.0 nM and ERK5 in human SN12C cells as measured by MEF2 transcription with IC50 and IC90 values of 115.0 nM and 691.0 nM, respectively. Additionally, it inhibits rat FER, human EPHB3, and human EPHA5 with inhibition rates of 62.0%, 58.0%, and 43.0%, respectively. Despite its potent enzymatic inhibition, it has low cytotoxicity against human SN12C-CMV-Luc cells (IC50 > 30000.0 nM), indicating selective targeting. BAY885 also shows varied effects on cell viability, as a growth rate of 0.0 and 1.0 was observed in HEK293T cells, U2OS cells, and human fibroblasts, suggesting complex bioactivity across different cell lines. Thermal Shift Assays reveal that BAY885 affects protein domain stability, showing both stabilizing and destabilizing effects on different regions. It exhibits high potency in targeting MAPK7 (ERK5) with an IC50 of 35.0 nM in a biochemical affinity assay and in cellular contexts, making it a significant inhibitor of the MAPK7 enzyme. However, it shows low activity against various other kinases and moderate activity against SIGMAR1. Overall, BAY885 appears to intricately influence kinase signaling pathways and cellular processes regulated by ERK5 and related enzymes..
Note: Summary generated by AI. Data source: ChEMBL 
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | BAY885 is a new ERK5 inhibitor. |
| Targets&IC50 | ERK5:35 nM (IC50) |
| Molecular Weight | 515.53 |
| Formula | C25H28F3N7O2 |
| Cas No. | 2307249-33-6 |
| Smiles | CN1CCN(CC1)c1cnc2c(ncnc2c1)C1CCN(CC1)C(=O)c1ccc(OC(F)(F)F)cc1N |
| Relative Density. | 1.362 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||
| Solubility Information | DMSO: 16.67 mg/mL (32.34 mM), Sonication is recommended. | |||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1 mg/mL (1.94 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy BAY885 | purchase BAY885 | BAY885 cost | order BAY885 | BAY885 chemical structure | BAY885 formula | BAY885 molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.